PL432842A1 - LPS for use in inducing tolerance in an individual to food allergens causing IgE-mediated food allergies - Google Patents

LPS for use in inducing tolerance in an individual to food allergens causing IgE-mediated food allergies

Info

Publication number
PL432842A1
PL432842A1 PL432842A PL43284220A PL432842A1 PL 432842 A1 PL432842 A1 PL 432842A1 PL 432842 A PL432842 A PL 432842A PL 43284220 A PL43284220 A PL 43284220A PL 432842 A1 PL432842 A1 PL 432842A1
Authority
PL
Poland
Prior art keywords
lps
food
individual
inducing tolerance
mediated
Prior art date
Application number
PL432842A
Other languages
Polish (pl)
Inventor
Ewa Kozłowska
Nadzieja DRELA
Original Assignee
Uniwersytet Warszawski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Warszawski filed Critical Uniwersytet Warszawski
Priority to PL432842A priority Critical patent/PL432842A1/en
Priority to PCT/PL2021/050003 priority patent/WO2021162563A1/en
Publication of PL432842A1 publication Critical patent/PL432842A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Przedmiotem wynalazku jest LPS do zastosowania w indukowaniu u osobnika tolerancji na alergeny pokarmowe związane z alergiami pokarmowymi zależnymi od IgE, przy czym stosuje się LPS pochodzący z bakterii E. coli ze szczepu 0111:B4, który podaje się osobnikowi przed kontaktem z alergenem.The invention relates to a LPS for use in inducing tolerance in an individual to food allergens associated with IgE-dependent food allergies, wherein an E. coli LPS derived from the 0111: B4 strain is used which is administered to the subject prior to contact with the allergen.

PL432842A 2020-02-10 2020-02-10 LPS for use in inducing tolerance in an individual to food allergens causing IgE-mediated food allergies PL432842A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL432842A PL432842A1 (en) 2020-02-10 2020-02-10 LPS for use in inducing tolerance in an individual to food allergens causing IgE-mediated food allergies
PCT/PL2021/050003 WO2021162563A1 (en) 2020-02-10 2021-02-10 Lipopolysaccharides for treating food allergies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL432842A PL432842A1 (en) 2020-02-10 2020-02-10 LPS for use in inducing tolerance in an individual to food allergens causing IgE-mediated food allergies

Publications (1)

Publication Number Publication Date
PL432842A1 true PL432842A1 (en) 2021-08-16

Family

ID=75439422

Family Applications (1)

Application Number Title Priority Date Filing Date
PL432842A PL432842A1 (en) 2020-02-10 2020-02-10 LPS for use in inducing tolerance in an individual to food allergens causing IgE-mediated food allergies

Country Status (2)

Country Link
PL (1) PL432842A1 (en)
WO (1) WO2021162563A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042994A2 (en) * 1999-01-21 2000-07-27 North Shore-Long Island Jewish Research Institute Inhibition of bacterial dissemination
DE10013539B4 (en) * 2000-03-20 2006-07-13 Pharma-Zentrale Gmbh Escherichia coli lipopolysaccharides, process for their preparation and their uses
DE10125179A1 (en) * 2001-05-23 2002-12-05 Laves Ralph Georg Use of LPS to treat intestinal inflammatory processes
US8563523B2 (en) * 2007-09-07 2013-10-22 University Of Georgia Research Foundation, Inc. Synthetic lipid A derivative

Also Published As

Publication number Publication date
WO2021162563A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
McSorley et al. Immunomodulation by helminth parasites: defining mechanisms and mediators
CO2017013231A2 (en) Compositions comprising a bacterial strain of the genus parabacteroides
EP4424319A3 (en) Novel lactobacillus having various functions, and use thereof
CO2017013287A2 (en) Compositions comprising a bacterial strain of the genus Roseburia
ES2571856T3 (en) Use of nutritional compositions to prevent visceral adiposity
Helmby Helminths and our immune system: friend or foe?
BR112017003948A2 (en) composition
WO2016134291A3 (en) Mixed allergen compositions and methods for using the same
BR112019014397A2 (en) COMPOSITIONS OF NEISSERIA MENINGITIDIS AND METHODS OF THE SAME
BR112017004359A2 (en) proteinaceous meat analog having improved texture and extended shelf life
MX2018004715A (en) Composition comprising a mixture of molecules extracted from chrysanthellum indicum, cynara scolymus and lycium barbarum and use to act on carbohydrate and/or fat metabolism.
WO2010033274A3 (en) Nanoemulsion adjuvants
WO2004076481A3 (en) Hypoallergenic der p 1 and der p 3 proteins from dermatographoides pteronyssinus
CL2013003298A1 (en) Use of methotrexate because it is used to prepare a medicine, useful in the treatment of diseases that need treatment with a therapeutic product that produces autoimmunity, administered in a single cycle.
PH12020550903A1 (en) Immunostimulatory compositions
ECSP23029634A (en) BACILLUS PROBIOTIC COMPOSITIONS AND METHODS OF USE
Gómez Torrijos et al. Eosinophilic esophagitis: demographic, clinical, endoscopic, histologic, and atopic characteristics of children and teenagers in a Region in Cental Spain
PL432842A1 (en) LPS for use in inducing tolerance in an individual to food allergens causing IgE-mediated food allergies
BRPI0510659A (en) induction of an immune response against streptococcus pneumoniae polysaccharides
MX2021005465A (en) Nutrition bar for intermittent fasting-mimicking.
WO2006014907A3 (en) Use of parasitic biological agents for prevention and control of allergic and other ige-mediated disorders
Morrow et al. Regulatory aspects of allergen vaccines in the US
ATE290081T1 (en) PARIETARIA JUDAICA NS-LTP ANTIGEN VARIANTS, CORRESPONDING PHARMACEUTICAL COMPOSITIONS AND USE THEREOF
CO2019005851A2 (en) Manufacturing optimization of gl-2045, a multimerizing stradomer
BR112017017115A2 (en) Use of Antipathogenic Agent, Use of Down-Regulating Agent on an Extracellular Matrix-Associated Polypeptide, Method for Treating or Preventing Disease Associated with Secondary Infection in a Pathogen-Infected Person, Method for Treating a Pathogen-Infected Person, Article manufacturing or pharmaceutical composition, and method for treating influenza